secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069176
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Karyopharm Reports Q1 2025 Revenue of $30.0M, Net Loss of $23.5M; Phase 3 SENTRY Trial Passes Futility Analysis
--------------------------------------------------------------------------------

- Total revenue $30.0M; U.S. XPOVIO net product revenue $21.1M, impacted by $5.0M increase in product return reserve for expired 80 mg and 100 mg units.
- Phase 3 SENTRY trial (selinexor + ruxolitinib) passed futility analysis, is ~80% enrolled; target enrollment expected June/July 2025.
- Phase 2 XPORT-MF-035 data: selinexor monotherapy achieved SVR25 in 67% of evaluable patients vs 38% with physician's choice.
- Reaffirms full-year 2025 guidance: total revenue $140M–$155M, U.S. XPOVIO net product revenue $115M–$130M.
- Cash, cash equivalents and investments $70.3M as of March 31, 2025; exploring alternatives to extend cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025069176/0000950170-25-069176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025069176/kpti-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer